Passage Bio falls short of Nasdaq minimum stockholders' equity requirement
PASG•Passage Bio received a Nasdaq noncompliance notice on November 12, 2026, after reporting $50,000 in stockholders' equity as of September 30, below the $2.5 million minimum. The notice has no immediate effect on its listing; the company expects planned mergers with Remix Therapeutics to restore compliance.
1. Equity below minimum
Passage Bio received a Nasdaq noncompliance notice on November 12, 2026, for failing to meet the minimum stockholders' equity requirement. Its stockholders' equity totaled $50,000 as of September 30, 2026, below the Nasdaq Capital Market's $2.5 million minimum. The notice has no immediate effect on the company's listing.
2. Planned mergers
Passage Bio expects its planned mergers with Remix Therapeutics to restore compliance, with closing subject to Nasdaq listing approval. If the mergers do not close within Nasdaq's permitted compliance period, Passage Bio intends to submit a plan to regain compliance.




